The analysis demonstrated that patients receiving pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experienced significantly more good days and reduced hospital stays compared to those treated with standard therapy (ST). Specifically, PIPAC patients had a median of 181 good days at six months versus 131 days for ST, and an overall survival median of 11.3 months compared […]
Category: Cytoreductive Surgery & Peritoneum
Diagnostic laparoscopy shows strong accuracy for cancer treatment selection
A systematic review of 25 studies involving 3,820 patients found that diagnostic laparoscopy (DL) exhibits high diagnostic performance in selecting patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The pooled positive predictive value was 93.04%, with sensitivity at 98.26% and specificity at 83.67%. Further analysis identified high accuracy in ovarian cancer cases, […]
Tumor nodules show higher pathology confirmation rates in surgery.
A multicenter study of 707 patients revealed significant variability in surgical peritoneal cancer index (SPCI) recording and lesion pathology confirmation across 10 centers. Notably, ‘tumor nodules’ demonstrated a higher incidence of pathologically confirmed disease, particularly with a lesion score of 2/3 (63.1%) versus 1 (31.5%, p < 0.001). Additionally, the absence of significant differences in […]
Gastrectomy achieves long-term survival in advanced pseudomyxoma cases.
Analysis of 120 gastrectomies for appendiceal pseudomyxoma peritonei (PMP) over 20 years revealed a median survival of 104 months and a 10-year overall survival rate of 47%. While complications were observed in 32% of cases, 90-day mortality was low at 1.75%. Outcomes improved over decades, with 82.2% achieving complete cytoreduction (CCR) in the later period, […]
More PIPAC treatments correlate with improved patient survival
Conducting three or more pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures significantly enhances survival among patients with unresectable peritoneal surface malignancies. In a cohort of 346 patients undergoing 1200 treatments, approximately two-thirds completed at least three procedures. Disease progression was the primary reason for treatment cessation in over half of cases. The findings suggest that increasing […]
Circulating tumor cells predict poorer survival outcomes in colorectal cancer patients with peritoneal metastases
Circulating tumor cells (CTCs) detected in 37% of colorectal cancer patients with peritoneal metastases were associated with shorter recurrence-free and overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Patients with CTCs post-neoadjuvant treatment had significantly worse outcomes. Adjuvant therapy improved prognosis in CTC-positive patients but not in CTC-negative ones. CTCs may serve as a […]
Circulating Exosomal MicroRNA Panel Predicts Peritoneal Metastasis in Advanced Gastric Cancer
A circulating exosomal microRNA panel, robustly predicting peritoneal metastasis in advanced gastric cancer patients, was developed and validated with remarkable accuracy. The risk-stratification model, combined with currently used tumor markers, significantly outperformed conventional clinical factors in predicting metastasis. This novel liquid biopsy assay shows potential for improved patient selection and management, offering clinical impact in […]
CRS-HIPEC Improves Survival in Malignant Peritoneal Mesothelioma
Study of 118 patients with malignant peritoneal mesothelioma revealed cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) led to longer overall and progression-free survival. The platinum-pemetrexed combination was effective for metastatic patients and those medically inoperable. Non-surgical patients had poorer prognoses. CRS-HIPEC emerged as a safe and effective treatment, offering better survival outcomes and […]
Improved Survival with CRS + HIPEC in HCC-PM Patients
CRS + HIPEC provides significant benefits to HCC-PM patients, with 89.0% 1-year and 3-year OS rates. Some patients achieved prolonged PFS, enhancing treatment options for this challenging condition. Incorporating CRS + HIPEC into the treatment regimen is a strategic therapeutic choice for HCC-PM patients, supported by the study’s findings of extended survival outcomes. Journal Article […]
Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced Colorectal Cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery shows potential in preventing peritoneal metastases in high-risk colorectal cancer. Recent randomized controlled trials, including Hipect4, demonstrate improved locoregional disease control with HIPEC, without an increase in complications. Despite negative results in trials like Prophylochip and Colopec, the methodology and patient selection criteria provide valuable insights. Ongoing […]